Agios Obtains Exclusive Global License for Oscotec’s Cevidoplenib, a Next-Generation SYK Inhibitor

Agios and Oscotec have entered into an exclusive global license agreement for the development and commercialization of cevidoplenib, a next-generation SYK inhibitor. The agreement grants Agios exclusive worldwide rights to develop and commercialize cevidoplenib.

Under the terms of the agreement, Agios will be responsible for all future development and commercialization activities for cevidoplenib across the globe. Oscotec will receive an upfront payment and is eligible to receive additional payments based on the achievement of specific development, regulatory, and commercial milestones, as well as royalties on future sales of cevidoplenib. The agreement signifies a strategic move for Agios to expand its portfolio and leverage Oscotec’s innovative research in the field of SYK inhibition.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI